Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study

BACKGROUND: Extended dosing of the erythropoiesis-stimulating agent (ESA) darbepoetin alfa (DA) once biweekly or monthly reduces anaemia treatment burden. This observational study assessed outcomes and dosing patterns in patients with chronic kidney disease not on dialysis (CKD-NoD) commencing exten...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nephrol Dial Transplant
Autors principals: Galle, Jan-Christoph, Addison, Janet, Suranyi, Michael G., Claes, Kathleen, Di Giulio, Salvatore, Guerin, Alain, Herlitz, Hans, Kiss, István, Farouk, Mourad, Manamley, Nick, Wirnsberger, Gerhard, Winearls, Christopher
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
CLINICAL SCIENCE
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5146706/
https://ncbi.nlm.nih.gov/pubmed/27190334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfw047
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars